LivaNova PLC research snapshot
LIVN AI stock analysis reads LivaNova as a specialized medical technology company with two operating segments: Neuromodulation (vagus nerve stimulation therapy for drug-resistant epilepsy, depression, and the FDA-approved aura6000 system for moderate to severe obstructive sleep apnea) and Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion systems, and perfusion products). At the August 3, 2026 data cutoff, LIVN closed at $80.14 on July 31, 2026 with a verified market value near $4.40 billion. The bull case depends on aura6000 commercial launch execution, continued VNS Therapy adoption, positive OSPREY and PolySync clinical data, cardiopulmonary recovery, margin expansion toward med-tech peer levels, and the company raised its full-year 2026 revenue and adjusted EPS guidance after a Q1 beat. The caution is that the stock trades near $80.14 at roughly 41x trailing earnings, TTM EPS of $1.95 still includes the prior-year restructuring period, the forward P/E near 18.5x relies on adjusted earnings growth of 7% to 8% revenue and $4.20 to $4.30 adjusted EPS guidance, competitive pressure exists in both segments, and the company has a history of CEO turnover and acquisition integration challenges.
Current price
$80.14
Market cap
$4.40 billion verified market cap
AI score
66 / 100
Rating
Specialized medical technology company with an FDA-approved aura6000 OSA growth catalyst, recovering fundamentals, a raised FY2026 outlook, and meaningful competitive plus valuation risk
Trend status
Neutral to constructive technical trend after a pullback from the 52-week high near $85.27, with price near the 50-day moving average around $78.79 and well above the 200-day moving average near $66.46
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | LivaNova sells implantable VNS therapy devices for epilepsy and depression, cardiopulmonary bypass products for cardiac surgery, and launched aura6000 for obstructive sleep apnea after FDA premarket approval in March 2026. | Medium-high |
| Moat | VNS Therapy has FDA approval, clinical evidence, an implanted base, and physician training that create switching costs. Cardiopulmonary products compete on quality and regulatory compliance. aura6000 faces a moat-building challenge against Inspire Medical in OSA. | Medium |
| Management | CEO Vladimir Makatsaria joined in March 2024 with a medical device and pharmaceutical background. The team is relatively new, added a Cardiopulmonary president and a chief legal officer in 2026, and faces execution tests on aura6000 launch and margin improvement. | Medium |
| Financial trend | FY2025 revenue grew 10.74% to $1.388B with positive operating income of $182.71M, but GAAP net income was negative $242.5M due to one-time items. Q1 2026 grew 14.33% to $362.3M with net income of $22.29M and adjusted EPS of $0.98. TTM net income was $107.1M. | Medium-high |
| Valuation | At $80.14, verified math shows about 41x trailing EPS, 3.63x book value, 27.35x FCF per share, and 3.07x sales. Forward P/E near 18.5x reflects the raised FY2026 adjusted EPS guidance of $4.20 to $4.30. | Medium-high |
| Technical trend | The stock pulled back from a 52-week high near $85.27 to $80.14, trading near the 50-day moving average at $78.79 and well above the 200-day moving average at $66.46. RSI near 50 suggests the recent momentum is neither overbought nor oversold. | Medium |
| Risk level | Risk is elevated due to competitive pressure in OSA from Inspire Medical, cardiopulmonary market cyclicality, regulatory and reimbursement risk for VNS and aura6000, short interest near 7.4% of float, and turnaround execution risk under a relatively new management team. | Medium |
| AI confidence | Descriptive confidence is high because SEC filing and exchange data are available and reconciled. Forecast confidence is medium because product launch adoption rates, competitive dynamics, and margin trajectory are uncertain. | High data confidence |
| Investment certainty | Investment certainty is medium-low at this price. LIVN has interesting product franchises and a potential growth catalyst in aura6000, but the trailing P/E near 41x prices in significant improvement and leaves limited room for execution misses. | Medium-low |
LIVN AI stock forecast
The LIVN AI stock forecast is scenario-based, not a precise price prediction. Using the August 3, 2026 research cutoff, a reference price of $80.14, and the raised FY2026 adjusted EPS guidance of $4.20 to $4.30, the valuation range depends on aura6000 commercial success, cardiopulmonary recovery, margin trajectory, and the multiple the market assigns.
$105 to $125
More likely if aura6000 OSA commercial launch gains rapid adoption with strong physician and patient uptake, Q2 2026 results on August 5, 2026 beat estimates, VNS Therapy maintains steady growth, cardiopulmonary margins expand, and the market assigns a forward P/E near 25x or more on improved earnings power.
$80 to $95
More likely if the forward P/E near 18.5x proves fair, adjusted EPS grows toward the $4.20 to $4.30 guidance range, revenue growth near 7% to 8% holds, and the stock trades in a range consistent with the analyst consensus price target of $84.80.
$55 to $68
More likely if aura6000 launch disappoints relative to Inspire Medical competition, VNS Therapy faces pricing pressure or reimbursement changes, cardiopulmonary revenue stagnates, or the company reports EPS or margin misses that cause the forward multiple to contract toward the low to mid teens.
LIVN AI technical analysis
LIVN AI technical analysis is neutral to constructive as of the August 3, 2026 data cutoff. The stock closed at $80.14 on July 31, 2026, after pulling back from a 52-week high near $85.27. The 52-week range spans $41.02 to $85.27, and the stock is up roughly 82% over the trailing 52 weeks. The 50-day moving average sits at $78.79, so price is hovering right around it, while the 200-day moving average at $66.46 provides a well-below support reference. RSI near 50.38 and 20-day average volume near 558,000 suggest a balanced setup heading into the August 5, 2026 earnings report.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $80.14 | StockAnalysis and WallStreetZen July 31, 2026 closing quote, used as the reference price for valuation and market-cap math. |
| Immediate support | $75 to $78 | The zone around and just below the 50-day moving average at $78.79, where the recent pullback could find buying interest. |
| Deeper support | $66 to $70 | The 200-day moving average near $66.46 and the surrounding zone represent a deeper retracement reference if the uptrend stalls. |
| Near resistance | $82 to $85.27 | The recent intraday area and the 52-week high near $85.27 are the immediate overhead resistance. A clean break above them would signal trend continuation. |
| 50-day moving average | $78.79 | Price is trading near this level after the pullback, so it is a watch level for trend balance. |
| 200-day moving average | $66.46 | The 200-day MA is well below the current price, indicating the longer-term trend is still upward. |
| Momentum | RSI near 50 | RSI of 50.38 is balanced, suggesting the recent pullback has released some overbought pressure without turning the trend negative. |
| Volume | 20-day average near 558,000 | Average volume around 558,000 shares is moderate for LIVN, with no strong volume signal before the upcoming earnings report. |
| Volatility | Beta near 0.86 | LIVN has below-market volatility by beta, but product launch announcements, clinical data, and quarterly earnings can still produce sharp moves. |
| Invalidation | Close below $75, then below $66 | A close below $75 would suggest the pullback is deepening. A move below the 200-day moving average near $66 would put the bear scenario in focus. |
LIVN AI trading strategy
The LIVN AI trading strategy below is a rules-based research framework, not personal financial advice. It links price action with Q2 2026 earnings on August 5, 2026, aura6000 commercial launch data, OSPREY and PolySync clinical follow-up, VNS Therapy adoption, cardiopulmonary segment trends, and valuation discipline.
Watch for LIVN to reclaim the $82 to $85.27 resistance zone with volume near or above the 20-day average while Q2 2026 results on August 5, 2026 confirm revenue growth, adjusted EPS progress, and positive aura6000 commercial traction.
Treat a failed move above the 52-week high followed by a close below $78 as a warning that the pullback is broadening, and a close below $75 as a stronger trend warning.
If LIVN pulls back toward the $75 to $78 zone without a negative catalyst such as an earnings miss, regulatory setback, or competitive threat, compare the reset price with the raised FY2026 adjusted EPS guidance of $4.20 to $4.30 and the forward valuation.
Do not average down based on the stock being up about 82% over the past year. Require evidence that the growth thesis is intact and that any pullback is volume-driven exhaustion rather than fundamental deterioration.
Track Q2 2026 earnings on August 5, 2026, aura6000 launch metrics, OSPREY study results, VNS Therapy revenue growth, cardiopulmonary segment margins, operating cash flow, debt levels, short interest, and forward guidance.
Lower the rating if revenue growth slows below 7% while the stock trades above a 20x forward P/E, or if competitive data from Inspire Medical or other OSA therapies weakens the aura6000 market opportunity.
Investment research summary
Patients and surgeons pay LivaNova because VNS Therapy provides a proven electrical stimulation treatment for drug-resistant epilepsy and depression when medications fail, cardiopulmonary bypass products are essential equipment for open-heart surgery procedures, and the aura6000 system offers a new FDA-approved option for obstructive sleep apnea.
LIVN benefits from FDA-approved VNS technology with clinical evidence and an implanted patient base. Physician training and patient outcomes create switching costs. The moat is being tested in OSA by Inspire Medical, which has a competing hypoglossal nerve stimulation device with a head start in the market.
The thesis fails if aura6000 commercial launch underperforms expectations, Inspire Medical or another competitor dominates the OSA neuromodulation market, VNS Therapy faces reimbursement cuts, cardiopulmonary revenue stagnates, or margin improvement plans fall short of the raised guidance.
CEO Vladimir Makatsaria was appointed in March 2024 and brings experience from Baxter, Abbott, and Johnson & Johnson. The company added a Cardiopulmonary president in June 2026 and a chief legal officer effective August 2026, and it has a history of prior CEO turnover and acquisition integration challenges.
LivaNova operates in beneficial med-tech trends: aging populations driving cardiac surgery volumes, increasing awareness of drug-resistant epilepsy treatment options, and growing demand for non-pharmaceutical OSA treatments. The neuromodulation market is expanding but competitive.
At about 41x trailing EPS and 27.35x FCF per share, LIVN is priced for a turnaround. The forward P/E near 18.5x against raised adjusted EPS guidance of $4.20 to $4.30 is more reasonable, but margin of safety is limited at the current price given execution risk and competitive response.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LIVN quote reference | $80.14 closing price as of July 31, 2026, with a day range of $79.29 to $81.78 | StockAnalysis and WallStreetZen LIVN pages | August 3, 2026 |
| Market capitalization verification | $4.40 billion market cap, verified at 0.05% deviation from $80.14 x 54.93 million shares | Pineify financial_rigor.py using StockAnalysis data | August 3, 2026 |
| Shares outstanding | Approximately 54.93 million shares (54,933,538), confirmed by WallStreetZen | WallStreetZen and StockAnalysis | August 3, 2026 |
| TTM financial data | $1.43B revenue, $107.1M net income, $1.95 EPS, $161.04M free cash flow, $245.59M operating cash flow | StockAnalysis statistics and WallStreetZen | August 3, 2026 |
| FY2025 annual results (SEC 10-K) | $1.388B revenue (+10.74%), operating income $182.71M, GAAP net income negative $242.5M due to one-time items, diluted EPS negative $4.45 | SEC XBRL and StockAnalysis financials | August 3, 2026 |
| FY2025 segment revenue | Cardiopulmonary $785.39M, Neuromodulation $592.81M, Other $9.86M | StockAnalysis segment data (S&P Global) | August 3, 2026 |
| Q1 2026 results | $362.3M revenue (+14.33% YoY), $22.29M net income, GAAP diluted EPS $0.40, adjusted EPS $0.98 vs $0.90 consensus | SEC XBRL and WallStreetZen earnings page | August 3, 2026 |
| FY2026 guidance | Revenue growth of 7.0% to 8.0% on a constant-currency basis and adjusted diluted EPS of $4.20 to $4.30, both raised on May 6, 2026 | Business Wire and TheFly coverage of Q1 2026 release | August 3, 2026 |
| Balance sheet strength | $539.71M cash and investments, roughly $334M to $343M total debt, net cash near $196M to $205M, book value $1.21B | StockAnalysis statistics | August 3, 2026 |
| Valuation metrics | Roughly 41x trailing P/E, 18.5x forward P/E, 0.93 PEG ratio, 3.07x price/sales, 3.63x price/book, 2.90x EV/revenue, 18.43x EV/EBITDA | Yahoo Finance and StockAnalysis statistics | August 3, 2026 |
| Profitability and returns | TTM gross margin 67.85%, profit margin 7.47%, return on assets 5.27%, return on equity 9.54% | StockAnalysis statistics | August 3, 2026 |
| Beta and volatility | Beta of 0.86 on a monthly 5-year basis | Yahoo Finance and StockAnalysis | August 3, 2026 |
| Technical trend | Stock up roughly 82% over the trailing 52 weeks, 52-week range of $41.02 to $85.27, 50-day MA $78.79, 200-day MA $66.46, RSI 50.38, short interest 7.44% of float | StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Buy consensus from 10 analysts, average price target $84.80, range $67 to $95; Mizuho raised its target to $95 on July 15, 2026 | StockAnalysis forecast and Yahoo Finance analyst insights | August 3, 2026 |
| CEO and management context | Vladimir Makatsaria is CEO and board director since March 2024; Alex Shvartsburg serves as CFO; Jette Nygaard-Andersen joined the board in June 2026 | Wikipedia LivaNova page and Business Wire | August 3, 2026 |
This LIVN AI stock analysis page is an informational research tool only and is not investment advice, a recommendation, or a promise of future return. Forecast scenarios are based on public data available at the stated cutoff date, use simplified assumptions, and can be wrong if business, market, regulatory, clinical, or valuation conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
